Apolipoprotein E genotype and schizophrenia: further negative evidence

Area of Science:

• Neuroscience
• Genetics

Background:

• Schizophrenia is a complex psychiatric disorder with a significant genetic component.
• Apolipoprotein E (ApoE) is a protein involved in lipid transport, with genetic variations that have been implicated in various neurological conditions.

Purpose of the Study:

• To examine the potential association between apolipoprotein E (ApoE) genotype and the risk of developing schizophrenia.
• To determine if ApoE genotype influences the age of onset in schizophrenia patients.

Main Methods:

• Genotyping of apolipoprotein E (ApoE) alleles (epsilon2, epsilon3, epsilon4) in 106 schizophrenia patients and 250 healthy controls using PCR, CfoI digestion, and agarose gel electrophoresis.
• Statistical analysis to compare allele and genotype frequencies between patient and control groups.

Main Results:

• No statistically significant differences in ApoE allele or genotype frequencies were observed between schizophrenia patients and healthy controls.
• A non-significant trend towards a higher frequency of the ApoE epsilon4 allele was noted in patients (9.0%) compared to controls (6.2%).
• The mean age of onset for schizophrenia was not significantly different between patients carrying the epsilon4 allele and those who did not.

Conclusions:

• The findings suggest that variations in the apolipoprotein E (ApoE) gene are not associated with schizophrenia susceptibility in the studied Spanish population.
• Apolipoprotein E (ApoE) genotypes do not appear to modify the age of disease onset in individuals with schizophrenia.